Received Mar 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | IM |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
hard time moving her arms and legs; did not receive the second Shingrix vaccine; muscle ache arms and legs; This non-serious case was reported by a consumer via call center representative and described the occurrence of muscle pain in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. In DEC-2020, the patient received the 1st dose of Shingrix (intramuscular, unknown deltoid) .5 ml. On an unknown date, the patient did not receive the 2nd dose of Shingrix. In DEC-2020, less than a month after receiving Shingrix, the patient experienced muscle pain (Verbatim: muscle ache arms and legs). On an unknown date, the patient experienced mobility decreased (Verbatim: hard time moving her arms and legs) and incomplete course of vaccination (Verbatim: did not receive the second Shingrix vaccine). The patient was treated with immunoglobulin g human (Igg). The outcome of the muscle pain and mobility decreased were resolved and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the muscle pain and mobility decreased to be related to Shingrix. It was unknown if the company considered the muscle pain and mobility decreased to be related to Shingrix. Additional Information: GSK Receipt Date: 12-MAR-2026 The batch number was not provided and a request for this information has been made.